Akari Therapeutics (AKTX) Accounts Payables (2011 - 2026)

Akari Therapeutics has disclosed Accounts Payables across 16 years of filings, most recently posting $8.6 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $8.6 million, down 33.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.6 million (down 33.87% YoY), and the FY2025 annual result was $8.8 million, down 29.31% from the prior year.
• Accounts Payables came in at $8.6 million for Q1 2026 at Akari Therapeutics, down from $8.8 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $13.1 million in Q1 2025 to a low of $947000.0 in Q4 2022.
• The 5-year median for Accounts Payables is $8.6 million (2026), against an average of $7.3 million.
• Across the five-year window, Accounts Payables slumped 47.05% in 2022 and surged 642.49% in 2024, its largest moves.
• Akari Therapeutics' Accounts Payables stood at $947000.0 in 2022, then surged by 76.45% to $1.7 million in 2023, then soared by 642.49% to $12.4 million in 2024, then declined by 29.31% to $8.8 million in 2025, then decreased by 1.47% to $8.6 million in 2026.
• The last three Accounts Payables figures came in at $8.6 million (Q1 2026), $8.8 million (Q4 2025), and $10.8 million (Q3 2025), per Business Quant data.